| 000 | 01713 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250516012642.0 | ||
| 264 | 0 | _c20110418 | |
| 008 | 201104s 0 0 eng d | ||
| 022 | _a1873-264X | ||
| 024 | 7 |
_a10.1016/j.jpba.2010.10.013 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKrishnaiah, Ch | |
| 245 | 0 | 0 |
_aDevelopment of a stability-indicating UPLC method for determining olanzapine and its associated degradation products present in active pharmaceutical ingredients and pharmaceutical dosage forms. _h[electronic resource] |
| 260 |
_bJournal of pharmaceutical and biomedical analysis _cMar 2011 |
||
| 300 |
_a667-73 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Validation Study | ||
| 650 | 0 | 4 |
_aAntipsychotic Agents _xanalysis |
| 650 | 0 | 4 |
_aBenzodiazepines _xanalysis |
| 650 | 0 | 4 | _aChromatography, High Pressure Liquid |
| 650 | 0 | 4 |
_aDrug Contamination _xprevention & control |
| 650 | 0 | 4 | _aDrug Stability |
| 650 | 0 | 4 |
_aHot Temperature _xadverse effects |
| 650 | 0 | 4 | _aHydrogen-Ion Concentration |
| 650 | 0 | 4 | _aLimit of Detection |
| 650 | 0 | 4 | _aOlanzapine |
| 650 | 0 | 4 | _aOxidation-Reduction |
| 650 | 0 | 4 | _aQuality Control |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aSpectrometry, Mass, Electrospray Ionization |
| 650 | 0 | 4 | _aTandem Mass Spectrometry |
| 650 | 0 | 4 | _aTechnology, Pharmaceutical |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aUltraviolet Rays _xadverse effects |
| 700 | 1 | _aVishnu Murthy, M | |
| 700 | 1 | _aKumar, Ramesh | |
| 700 | 1 | _aMukkanti, K | |
| 773 | 0 |
_tJournal of pharmaceutical and biomedical analysis _gvol. 54 _gno. 4 _gp. 667-73 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jpba.2010.10.013 _zAvailable from publisher's website |
| 999 |
_c20373112 _d20373112 |
||